AVEO Pharmaceuticals Company Profile (NASDAQ:AVEO)

About AVEO Pharmaceuticals (NASDAQ:AVEO)

AVEO Pharmaceuticals logoAVEO Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's platform delivers insights into cancer and related disease. The Company's product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors. Tivozanib is designed to optimize VEGF blockade while minimizing off-target toxicities. Ficlatuzumab is a Hepatocyte Growth Factor (HGF) inhibitory antibody. AV-203 is an anti-ErbB3 monoclonal antibody with ErbB3 affinity. Its preclinical studies suggest that neuregulin1 (NRG1) levels predict AV-203 antitumor activity in preclinical models. AV-380 is a humanized Immunoglobulin G 1 (IgG1) inhibitory monoclonal antibody. AV-380 targets growth differentiating factor 15 (GDF15).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:AVEO
  • CUSIP: 05358810
  • Web: www.aveooncology.com
Capitalization:
  • Market Cap: $446.02 million
  • Outstanding Shares: 118,307,000
Average Prices:
  • 50 Day Moving Avg: $3.26
  • 200 Day Moving Avg: $1.68
  • 52 Week Range: $0.50 - $4.24
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -10.47
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $4 million
  • Price / Sales: 111.50
  • Book Value: ($0.17) per share
  • Price / Book: -22.18
Profitability:
  • EBIDTA: ($31,560,000.00)
  • Net Margins: -1,316.79%
  • Return on Equity: -836.92%
  • Return on Assets: -89.76%
Debt:
  • Debt-to-Equity Ratio: -0.83%
  • Current Ratio: 2.82%
  • Quick Ratio: 2.82%
Misc:
  • Average Volume: 8.38 million shs.
  • Beta: 1.4
  • Short Ratio: 1
 

Frequently Asked Questions for AVEO Pharmaceuticals (NASDAQ:AVEO)

What is AVEO Pharmaceuticals' stock symbol?

AVEO Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVEO."

How were AVEO Pharmaceuticals' earnings last quarter?

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) announced its quarterly earnings results on Thursday, May, 4th. The company reported ($0.12) EPS for the quarter, beating analysts' consensus estimates of ($0.12) by $0.00. The company earned $2.53 million during the quarter. AVEO Pharmaceuticals had a negative return on equity of 836.92% and a negative net margin of 1,316.79%. View AVEO Pharmaceuticals' Earnings History.

Where is AVEO Pharmaceuticals' stock going? Where will AVEO Pharmaceuticals' stock price be in 2017?

2 analysts have issued twelve-month price targets for AVEO Pharmaceuticals' stock. Their predictions range from $3.00 to $4.50. On average, they anticipate AVEO Pharmaceuticals' stock price to reach $3.75 in the next year. View Analyst Ratings for AVEO Pharmaceuticals.

Are investors shorting AVEO Pharmaceuticals?

AVEO Pharmaceuticals saw a increase in short interest during the month of August. As of August 15th, there was short interest totalling 9,154,945 shares, an increase of 43.5% from the July 31st total of 6,379,318 shares. Based on an average daily trading volume, of 2,993,809 shares, the days-to-cover ratio is presently 3.1 days. Approximately 10.4% of the shares of the stock are sold short.

Who are some of AVEO Pharmaceuticals' key competitors?

Who are AVEO Pharmaceuticals' key executives?

AVEO Pharmaceuticals' management team includes the folowing people:

  • Michael P. Bailey, President, Chief Executive Officer, Director
  • Matthew Dallas, Chief Financial Officer
  • Michael N. Needle M.D., Chief Medical Officer
  • Henri A. Termeer, Lead Out Side Director
  • Kenneth M. Bate, Independent Director
  • Anthony B. Evnin Ph.D., Independent Director
  • Robert C. Young M.D., Independent Director

Who owns AVEO Pharmaceuticals stock?

AVEO Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include NEA Management Company LLC (14.83%), RA Capital Management LLC (7.64%), Vanguard Group Inc. (3.22%), Sphera Funds Management LTD. (1.99%), EAM Investors LLC (0.81%) and Evercore Wealth Management LLC (0.15%). View Institutional Ownership Trends for AVEO Pharmaceuticals.

Who sold AVEO Pharmaceuticals stock? Who is selling AVEO Pharmaceuticals stock?

AVEO Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD. and Bank of New York Mellon Corp. View Insider Buying and Selling for AVEO Pharmaceuticals.

Who bought AVEO Pharmaceuticals stock? Who is buying AVEO Pharmaceuticals stock?

AVEO Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including RA Capital Management LLC, Vanguard Group Inc., EAM Investors LLC, Clear Harbor Asset Management LLC, Fore Research & Management LP and Cannell Peter B & Co. Inc.. View Insider Buying and Selling for AVEO Pharmaceuticals.

How do I buy AVEO Pharmaceuticals stock?

Shares of AVEO Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AVEO Pharmaceuticals' stock price today?

One share of AVEO Pharmaceuticals stock can currently be purchased for approximately $3.77.


MarketBeat Community Rating for AVEO Pharmaceuticals (NASDAQ AVEO)
Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  170 (Vote Outperform)
Underperform Votes:  169 (Vote Underperform)
Total Votes:  339
MarketBeat's community ratings are surveys of what our community members think about AVEO Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for AVEO Pharmaceuticals (NASDAQ:AVEO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $3.75 (0.53% downside)

Analysts' Ratings History for AVEO Pharmaceuticals (NASDAQ:AVEO)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/28/2017Piper Jaffray CompaniesBoost Price TargetOverweight$3.80 -> $4.50HighView Rating Details
7/13/2017FBR & CoReiterated RatingOutperform$3.00HighView Rating Details
(Data available from 9/20/2015 forward)

Earnings

Earnings History for AVEO Pharmaceuticals (NASDAQ:AVEO)
Earnings by Quarter for AVEO Pharmaceuticals (NASDAQ:AVEO)
Earnings History by Quarter for AVEO Pharmaceuticals (NASDAQ AVEO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/4/2017Q1 2017($0.12)($0.12)$2.53 millionViewN/AView Earnings Details
11/4/2016Q3 2016($0.12)($0.07)$0.99 millionViewN/AView Earnings Details
5/10/2016Q1($0.12)($0.13)$1.00 million$1.20 millionViewN/AView Earnings Details
3/15/2016Q415($0.04)($0.11)$3.60 millionViewN/AView Earnings Details
11/9/2015Q315($0.09)$0.14$15.16 millionViewN/AView Earnings Details
8/10/2015Q2($0.16)($0.10)$0.13 millionViewListenView Earnings Details
5/7/2015Q115($0.27)($0.21)$0.13 millionViewN/AView Earnings Details
3/6/2015Q314($0.28)($0.27)$0.12 millionViewListenView Earnings Details
11/5/2014Q3 2014($0.27)($0.28)$0.33 million$0.87 millionViewN/AView Earnings Details
8/11/2014Q214($0.38)($0.35)$0.35 million$1.85 millionViewN/AView Earnings Details
5/7/2014Q1 2014($0.33)($0.12)$0.38 million$15.29 millionViewN/AView Earnings Details
3/13/2014Q413($0.33)($0.32)$0.14 million$0.32 millionViewListenView Earnings Details
11/4/2013Q313($0.47)($0.47)$0.23 million$0.32 millionViewN/AView Earnings Details
8/1/2013Q213($0.56)($0.62)$4.30 million$0.32 millionViewN/AView Earnings Details
4/29/2013Q1 2013($0.72)($0.69)$2.52 million$0.32 millionViewListenView Earnings Details
2/13/2013Q4 2012($0.77)($0.49)$14.49 million$15.53 millionViewN/AView Earnings Details
10/30/2012Q312($0.87)($0.69)$6.57 million$1.02 millionViewN/AView Earnings Details
8/2/2012($0.82)($0.68)ViewN/AView Earnings Details
5/3/2012($0.78)($0.77)ViewN/AView Earnings Details
2/14/2012($0.64)($0.58)ViewN/AView Earnings Details
11/2/2011($0.46)($0.55)ViewN/AView Earnings Details
7/28/2011($0.80)($0.16)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for AVEO Pharmaceuticals (NASDAQ:AVEO)
2017 EPS Consensus Estimate: ($0.55)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.13)($0.13)($0.13)
Q2 20171($0.10)($0.10)($0.10)
Q3 20171($0.17)($0.17)($0.17)
Q4 20171($0.15)($0.15)($0.15)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for AVEO Pharmaceuticals (NASDAQ:AVEO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for AVEO Pharmaceuticals (NASDAQ:AVEO)
Insider Ownership Percentage: 4.70%
Institutional Ownership Percentage: 53.76%
Insider Trades by Quarter for AVEO Pharmaceuticals (NASDAQ:AVEO)
Institutional Ownership by Quarter for AVEO Pharmaceuticals (NASDAQ:AVEO)
Insider Trades by Quarter for AVEO Pharmaceuticals (NASDAQ:AVEO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/28/2017Equity Opportunities Iv GrowthMajor ShareholderBuy6,000,000$0.50$3,000,000.00View SEC Filing  
1/16/2015Matthew D DallasVPSell3,075$0.82$2,521.50View SEC Filing  
1/7/2015Michael P BaileyCEOSell4,484$0.80$3,587.20View SEC Filing  
1/30/2014Joseph VittiglioSVPSell5,430$1.64$8,905.20View SEC Filing  
3/14/2013David Brannon JohnstonCFOSell1,061$7.34$7,787.74View SEC Filing  
3/7/2013Henri A TermeerDirectorBuy55,499$6.73$373,508.27View SEC Filing  
12/13/2012Ngoc Tuan HaCEOBuy75,000$6.65$498,750.00View SEC Filing  
12/13/2012Robert C YoungDirectorBuy2,371$6.78$16,075.38View SEC Filing  
12/3/2012Robert C YoungDirectorBuy1,250$6.41$8,012.50View SEC Filing  
9/13/2012David Brannon JohnstonCFOSell1,386$10.60$14,691.60View SEC Filing  
8/8/2012Robert C YoungDirectorBuy1,000$8.63$8,630.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for AVEO Pharmaceuticals (NASDAQ:AVEO)
Latest Headlines for AVEO Pharmaceuticals (NASDAQ:AVEO)
Source:
DateHeadline
baystreet.ca logoAVEO Flat on New Study with EUSA
www.baystreet.ca - September 20 at 4:59 PM
reuters.com logoBRIEF-AVEO Oncology and EUSA Pharma announce TiNivo combination study opt-in
www.reuters.com - September 20 at 4:59 PM
finance.yahoo.com logoAVEO Oncology and EUSA Pharma Announce TiNivo Combination Study Opt-in
finance.yahoo.com - September 20 at 4:59 PM
americanbankingnews.com logo-$0.05 Earnings Per Share Expected for AVEO Pharmaceuticals, Inc. (AVEO) This Quarter
www.americanbankingnews.com - September 18 at 6:20 PM
seekingalpha.com logoAVEO Pharmaceuticals (AVEO) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 13 at 10:25 PM
finance.yahoo.com logoAVEO Oncology Announces Receipt of Payments from EUSA Pharma and CANbridge
finance.yahoo.com - September 13 at 5:24 PM
finance.yahoo.com logoShould You Have AVEO Pharmaceuticals Inc’s (AVEO) In Your Portfolio?
finance.yahoo.com - September 13 at 5:24 PM
finance.yahoo.com logoETFs with exposure to AVEO Pharmaceuticals, Inc. : September 9, 2017
finance.yahoo.com - September 9 at 2:41 AM
finance.yahoo.com logoToday's Research Reports on Trending Tickers: AVEO Pharmaceuticals, Inc. and Celldex Therapeutics, Inc.
finance.yahoo.com - September 8 at 4:37 PM
finance.yahoo.com logoAVEO Oncology to Present at Upcoming Conferences
finance.yahoo.com - September 5 at 5:48 PM
americanbankingnews.com logoAVEO Pharmaceuticals, Inc. (AVEO) Expected to Announce Earnings of -$0.05 Per Share
www.americanbankingnews.com - August 31 at 6:12 AM
seekingalpha.com logoAVEO Oncology: EU Approval Pop Is Just The Beginning - Seeking Alpha
seekingalpha.com - August 31 at 3:35 AM
finance.yahoo.com logoFeatured Company News - AVEO Pharma's FOTIVDA(R) Licensed in EU for the Treatment of Advanced Renal Cell Carcinoma
finance.yahoo.com - August 30 at 5:29 PM
seekingalpha.com logoAveo On Target - Seeking Alpha
seekingalpha.com - August 29 at 9:35 PM
finance.yahoo.com logoHere's Why AVEO Pharmaceuticals Lost as Much as 19% Today
finance.yahoo.com - August 29 at 9:35 PM
fool.com logoHere's Why AVEO Pharmaceuticals Lost as Much as 19% Today
www.fool.com - August 29 at 4:55 PM
bizjournals.com logoBiotechs Jump on Major Acquisitions, FDA Clearance and Clinical Trial Developments
www.bizjournals.com - August 29 at 4:33 PM
seekingalpha.com logoAVEO's European Commission Approval Is Official
seekingalpha.com - August 29 at 4:33 PM
americanbankingnews.com logoAVEO Pharmaceuticals, Inc. (AVEO) Price Target Raised to $4.50 at Piper Jaffray Companies
www.americanbankingnews.com - August 28 at 4:26 PM
nasdaq.com logoUS STOCKS ON THE MOVE-Kite Pharma, Aveo Pharma, IXYS, Renren - Nasdaq
www.nasdaq.com - August 28 at 4:17 PM
marketwatch.com logoAVEO Pharma stock rises 6% after cancer drug gets approved in Europe - MarketWatch
www.marketwatch.com - August 28 at 4:17 PM
finance.yahoo.com logoAVEO Oncology Announces FOTIVDA® (tivozanib) Approved in the European Union for the Treatment of Advanced Renal Cell Carcinoma
finance.yahoo.com - August 28 at 4:17 PM
finance.yahoo.com logoAVEO Pharma stock rises 6% after cancer drug gets approved in Europe
finance.yahoo.com - August 28 at 4:17 PM
americanbankingnews.com logoAVEO Pharmaceuticals, Inc. (AVEO) Short Interest Update
www.americanbankingnews.com - August 26 at 1:20 AM
finance.yahoo.com logoETFs with exposure to AVEO Pharmaceuticals, Inc. : August 25, 2017
finance.yahoo.com - August 25 at 5:50 PM
americanbankingnews.com logoAVEO Pharmaceuticals Sees Unusually Large Options Volume (AVEO)
www.americanbankingnews.com - August 17 at 2:46 AM
americanbankingnews.com logoAVEO Pharmaceuticals, Inc. (AVEO) Rating Increased to Strong-Buy at BidaskClub
www.americanbankingnews.com - August 17 at 12:08 AM
finance.yahoo.com logoAVEO Pharmaceuticals, Inc. :AVEO-US: Earnings Analysis: Q2, 2017 By the Numbers : August 16, 2017
finance.yahoo.com - August 16 at 4:47 PM
finance.yahoo.com logoToday's Research Reports on Trending Tickers: AVEO Pharmaceuticals Inc. and Tandem Diabetes Care Inc.
finance.yahoo.com - August 15 at 5:07 PM
nasdaq.com logoAVEO Pharmaceuticals (AVEO) Q2 Loss Narrower than Expected - Nasdaq
www.nasdaq.com - August 10 at 3:54 PM
finance.yahoo.com logoAVEO Pharmaceuticals (AVEO) Q2 Loss Narrower than Expected
finance.yahoo.com - August 10 at 3:54 PM
reuters.com logoBRIEF-Aveo Pharmaceuticals Inc Q2 loss per share $0.30
www.reuters.com - August 10 at 2:24 AM
finance.yahoo.com logoAVEO Reports Second Quarter 2017 Financial Results and Provides Business Update
finance.yahoo.com - August 9 at 4:20 PM
finance.yahoo.com logoAVEO reports 2Q loss
finance.yahoo.com - August 9 at 4:20 PM
americanbankingnews.com logoAVEO Pharmaceuticals, Inc. (AVEO) Short Interest Up 98.9% in July
www.americanbankingnews.com - July 27 at 7:38 AM
zacks.com logoAVEO Pharmaceuticals (AVEO) Q2 Earnings: What's in Store?
www.zacks.com - July 26 at 4:52 PM
finance.yahoo.com logoAVEO Pharmaceuticals (AVEO) Q2 Earnings: What's in Store?
finance.yahoo.com - July 26 at 4:52 PM
finance.yahoo.com logoHere's Why AVEO Oncology Rose as Much as 15% Today
finance.yahoo.com - July 19 at 5:26 PM
americanbankingnews.com logo AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Given Consensus Recommendation of "Strong Buy" by Analysts
www.americanbankingnews.com - July 17 at 10:56 AM
americanbankingnews.com logoAVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Short Interest Up 63.9% in June
www.americanbankingnews.com - July 16 at 7:06 AM
bizjournals.com logoStock Performance Review on Biotech Industry -- Athersys, AVEO Pharma, Heat Biologics, and Ignyta
www.bizjournals.com - July 14 at 3:10 AM
americanbankingnews.com logoAVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Given "Outperform" Rating at FBR & Co
www.americanbankingnews.com - July 13 at 9:02 PM
finance.yahoo.com logoHere's Why AVEO Oncology Fell as Much as 12.7% Today
finance.yahoo.com - July 11 at 5:15 PM
nasdaq.com logoAVEO Pharmaceuticals (AVEO) Worth a Look: Stock Up 14.8% - Nasdaq
www.nasdaq.com - July 11 at 2:17 AM
finance.yahoo.com logoAVEO Pharmaceuticals Regulatory Decision from European Commission Expected Soon
finance.yahoo.com - July 10 at 9:15 PM
investorplace.com logoWhy AVEO Pharmaceuticals, Inc. (AVEO) Stock Is Soaring Today
investorplace.com - July 7 at 1:51 PM
americanbankingnews.com logoAVEO Pharmaceuticals, Inc. (AVEO) Rating Reiterated by FBR & Co
www.americanbankingnews.com - June 30 at 5:20 PM
finance.yahoo.com logo2 Biotech Stocks on Analysts’ Radar: Cara Therapeutics Inc (CARA) and AVEO Pharmaceuticals, Inc. (AVEO)
finance.yahoo.com - June 30 at 4:19 PM
finance.yahoo.com logoToday's Research Reports on Trending Tickers: AVEO Pharmaceuticals and Cara Therapeutics
finance.yahoo.com - June 28 at 4:21 PM
reuters.com logoBRIEF-Aveo Oncology gets $14 mln from Hercules Credit Facility and at-the-market stock offerings
www.reuters.com - June 28 at 1:56 AM

Social

Chart

AVEO Pharmaceuticals (AVEO) Chart for Wednesday, September, 20, 2017

This page was last updated on 9/20/2017 by MarketBeat.com Staff